Romero-Gómez M

Language: English
References: 11
Page: 296-298
PDF size: 74.20 Kb.

Text Extraction

Best J, et al.
Mycophenolic acid induces apoptosis of hepatic stellate cells in an in vitro model of HCV

Best J, et al. The activated form of mycophenolate mofetil (MMF), mycophenolic acid (MPA), is a highly effective immunosuppressant that lacks the nephrotoxicity associated with calcineurin inhibitors that is often used to prevent rejection post-organ transplantation.

REFERENCES

1. Henry SD, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, van der Laan LJ. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006; 131: 1452-62.

2. Pan Q, de Ruiter PE, Metselaar HJ, Kwekkeboom J, de Jonge J, Tilanus HW, Janssen HL, et al. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C virus infection in vitro and in vivo. Hepatology 2012; 55: 1673-83.

3. Pradere J-P, Kluwe J, de Minicis S, Jiao J-J, Gwak G-Y, Dapito DH, Jang M-K, et al. Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 2013; 58: 1461-73.

4. Fallowfield JA. Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011; 300: G709-G715.

5. Adams, Crawford D, Stuart K, House M, St Pierre T, Webb M, Ching H, et al. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective randomized controlled trial. Hepatology 2015; 14: (In Press).

6. Koehler EM, Sanna D, Hansen BE, van Rooij FJ, Heeringa J, Hofman A, Tiemeier H, et al. Serum liver enzymes are associated with all-cause mortality in an elderly population. Liver Int 2014; 34: 296-304.

7. Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol 2013; 59: 926-33.

8. Konishi I, Hiasa Y, Tokumoto Y, Abe M, Furukawa S, Toshimitsu K, Matsuura B, et al. Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus. Hepatol Res 2011; 41: 928-35.

9. Pattullo V, Duarte-Rojo A, Soliman W, Vargas-Vorackova F, Sockalingam S, Fantus IG, Allard J, et al. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C. Liver Int 2013; 33: 410-9.

10. Payen J-L, Pillard F, Mascarell V, Rivière D, Couzigou P, Kharlov N. Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy? Gastroentérologie Clin Biol 2009; 33: 8-14.

11. Brandt C, Pedersen BK. The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. J Biomed Biotechnol 2010; 2010: 520258.